ArticleNeuro-oncology2024

Response to the letter by Wang et al.: Selumetinib for plexiform neurofibroma: Advances and ongoing challenges.

Beom Hee Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.